Inactive Instrument

Press Releases Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Press Releases

Unlock all the news: Be the first to know and act before the market!

Aeterna Zentaris and Ceapro Complete Merger Transaction	06-03	GL
Aeterna Zentaris and Ceapro Complete Merger Transaction	06-03	AQ
Canadian Investment Regulatory Organization Trading Halt - CZO	06-03	AQ
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	05-29	GL
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	05-29	AQ
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	04-29	GL
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	04-29	AQ
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	03-28	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	03-12	GL
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	03-12	AQ
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	02-26	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	02-26	GL
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	02-23	GL
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	02-15	GL
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	02-15	AQ
Canadian Investment Regulatory Organization Trade Resumption - CZO	12-14	AQ
Canadian Investment Regulatory Organization Trading Halt - CZO	12-14	AQ
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company	12-14	AQ
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	12-13	GL
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	12-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ceapro Inc Toronto S.E.

Equities

CZO

CA1499071076

Press Releases

Filters